查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1941553

多形性胶质母细胞瘤治疗市场规模、份额和趋势分析报告：按疗法、最终用途、地区和细分市场预测（2026-2033 年）

Glioblastoma Multiforme Treatment Market Size, Share & Trends Analysis Report By Treatment (Surgery, Radiation Therapy, Chemotherapy), By End Use (Hospitals, Ambulatory Surgery Centers), By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

多形性胶质母细胞瘤治疗市场概况

2025年全球多形性胶质母细胞瘤治疗市场规模估计为40.4亿美元，预计2033年将达到78.7亿美元。

预计从 2026 年到 2033 年，该行业将以 8.69% 的复合年增长率成长。多形性胶质母细胞瘤 (GBM) 的盛行率不断上升及其带来的重大临床负担是 GBM 治疗行业的关键驱动因素。

越来越多的依证强化了替Temozolomide（TMZ）作为胶质母细胞瘤（GBM）治疗基石药物的地位。近期真实世界研究和Meta分析表明，将TMZ疗程延长至标准的六个疗程之后，可能带来额外的生存获益，尤其是在具有良好分子特征（例如MGMT启动子甲基化水平低和Ki-67表达低）的患者中。发表于2023年7月《神经肿瘤学进展》（Neuro-Oncology Advances）的Meta分析，检验了来自16项非随机研究和5项随机对照试验的2578例患者的数据。分析结果显示，延长疗程可使疾病进展风险降低28%，死亡风险降低29%，但这些获益大多是在回顾性队列研究中观察到的。这些发现凸显了进行更多随机试验以确定其作为辅助性治疗长期应用价值的必要性。此外，鑑于替莫唑胺的耐受性和一致的临床疗效，目前正在进行评估联合治疗的临床试验。

成本效益和广泛的可及性也是替莫唑胺（TMZ）在全球范围内被广泛应用的原因之一。学名药的推出降低了治疗成本，提高了患者的可及性，且不影响治疗效果。其良好的安全性和确切的疗效使其成为不同医疗体系中的首选治疗方案。 2023年3月发表于《临床肿瘤学杂誌》（Journal of Clinical Oncology）的一项IIa期研究评估了TMZ联合SurVaxM疫苗作为辅助性治疗治疗新诊断胶质母细胞瘤患者的疗效。结果显示，患者的中位无恶化生存期为11.4个月，总存活期为25.9个月，且免疫反应强劲，严重的疫苗相关副作用，支持了联合治疗的潜力。即使新的治疗方法不断涌现，许多治疗方法仍以TMZ为基础，这再次巩固了TMZ在胶质母细胞瘤标准治疗中的关键地位。

肿瘤电场疗法（TTF）在全球的普及速度持续加快，这得益于其应用范围的扩大和有利的医保政策。许多医疗系统已将TTF纳入医保报销范围，从而降低了合格患者的经济负担。截至2024年底，Novocure公司报告称，全球已有超过4,000名患者正在积极使用Optune Gio TTF系统，其中美国、德国、法国和日本等地区的普及率较高。不断增长的使用者群体反映出医生对该治疗方法的接受度不断提高。良好的治疗效果也推动了技术创新，人们正持续致力于技术升级和拓展至其他肿瘤类型。这些进展共同促成了TTF在进行性多形性胶质母细胞瘤治疗发展过程中的重要地位。

五年存活数据显示，不同治疗方法的存活率有显着差异：单纯放射线治疗（RT）的存活率为16.2%，而合併替Temozolomide（TMZ）治疗的存活率高达83.8%。这显示联合治疗具有显着的临床优势，尤其体现在Temozolomide对改善多形性胶质母细胞瘤患者预后的贡献。这些发现支持继续将替Temozolomide作为多形性胶质母细胞瘤治疗的基石，并强化了联合通讯协定中对化疗药物的需求。此外，这些发现也为医疗服务提供者倾向于采用综合治疗方法提供了证据，从而促进了联合治疗在临床实践中的应用。

从市场观点来看，存活率的提高将继续推动联合治疗的投资，进而带动对替莫唑胺（TMZ）等辅助性治疗的需求。製药公司有望利用这些进展，开发下一代治疗方法，例如免疫疗法和标靶治疗，以补充和增强TMZ的疗效。放射线治疗合併TMZ的高存活率将影响治疗指南，从而扩大保险覆盖范围，并提高医院和癌症中心的采用率。这种转变不仅将维持TMZ在胶质母细胞瘤（GBM）治疗市场的主导地位，也将为新型辅助性治疗创造机会。

目录

第一章调查方法和范围

第二章执行摘要

3. 多形性胶质母细胞瘤治疗市场变数、趋势和范围

  • 市场谱系展望
  • 市场动态
  • 商业环境分析
    • 产业分析—波特五力分析
    • PESTLE分析
    • 管道分析
    • 专利到期分析
    • 定价分析

第四章 多形性胶质母细胞瘤治疗市场：治疗业务分析

  • 按疗法分類的市场份额（2025 年和 2033 年）
  • 按治疗方法分類的市场规模、预测和趋势分析（2021-2033 年）
  • 外科手术
  • 放射线治疗
  • 化疗
  • 标靶治疗（Bevacizumab）
  • 肿瘤电场治疗（TTF）

5. 多形性胶质母细胞瘤治疗市场：依最终用途分類的业务分析

  • 按最终用途分類的市场份额（2025 年和 2033 年）
  • 按最终用途分類的市场规模、预测和趋势分析（2021年至2033年）
  • 医院
  • 诊所/门诊中心
  • 门诊手术中心
  • 其他的

第六章 多形性胶质母细胞瘤治疗市场：区域估算与趋势分析

  • 区域市场占有率分析（2025 年和 2033 年）
  • 区域市场概览
  • 市场规模及预测趋势分析（2021-2033）：
  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争情势

  • 参与公司概况
  • 企业市场分析
  • 公司分类
  • 策略规划
  • 公司简介/列表
    • Merck &Co., Inc.
    • Amgen, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Sun Pharmaceutical Industries Ltd.
    • Arbor Pharmaceuticals, LLC
    • Amneal Pharmaceuticals
    • Karyopharm Therapeutics, Inc.
    • Sumitomo Dainippon Pharma Oncology, Inc.（Boston Biomedical, Inc.）
Product Code: GVR-4-68039-527-3

Glioblastoma Multiforme Treatment Market Summary

The global glioblastoma multiforme treatment market size was estimated at USD 4.04 billion in 2025 and is projected to reach USD 7.87 billion by 2033, growing at a CAGR of 8.69% from 2026 to 2033. The rising prevalence of Glioblastoma Multiforme (GBM) and its significant clinical burden are critical drivers in the GBM treatment industry.

The expanding evidence base has reinforced temozolomide's (TMZ) role as a cornerstone in glioblastoma multiforme (GBM) treatment. Several recent real-world studies and meta-analyses have shown that continuing TMZ therapy beyond the standard six cycles may provide additional survival benefits, particularly in patients with favorable molecular features such as MGMT promoter methylation or low Ki-67 expression. A meta-analysis published in Neuro-Oncology Advances in July 2023 reviewed outcomes from 2,578 patients across 16 nonrandomized studies and 5 randomized controlled trials. The analysis found that extended therapy was linked to a 28% reduction in disease progression and a 29% decrease in mortality risk, though most of these benefits were observed in retrospective cohorts. These findings highlight the need for further randomized investigations to establish the definitive value of prolonged adjuvant use. In addition, ongoing trials are evaluating TMZ in combination with immunotherapies and tumor-treating fields, supported by its tolerability and consistent clinical performance.

Cost-effectiveness and broad availability have also contributed to the widespread uptake of TMZ worldwide. The introduction of generic formulations has reduced treatment expenses, improving access without compromising therapeutic outcomes. Its favorable safety profile and established efficacy make it a preferred choice across diverse healthcare systems. A Phase IIa trial, published in March 2023 in the Journal of Clinical Oncology, assessed the SurVaxM vaccine alongside adjuvant TMZ in newly diagnosed GBM patients. Results demonstrated a median progression-free survival of 11.4 months and an overall survival of 25.9 months, with robust immune responses and no severe vaccine-related side effects, underscoring the potential of combination approaches. As emerging therapies evolve, many continue to build on TMZ as a foundation, reinforcing its critical role in the standard management of GBM.

The global uptake of tumor treating fields (TTF) continues to accelerate, supported by broader access and favorable reimbursement policies. Many healthcare systems have included TTF among reimbursable treatment options, reducing financial hurdles for patients who qualify. By late 2024, Novocure reported more than 4,000 patients worldwide actively using its Optune Gio TTF system, with strong adoption in regions such as the United States, Germany, France, and Japan. This rising user base reflects growing physician confidence and patient acceptance of the therapy across both advanced and emerging healthcare settings. The positive outcomes are also driving innovation, with ongoing efforts focused on technological upgrades and expanding its use in other tumor types. Collectively, these developments are positioning TTF as an integral element in the evolving management of glioblastoma multiforme.

The five-year survival data shows a marked difference between treatment approaches, with radiation therapy (RT) alone resulting in a 16.2% survival rate compared to 83.8% when combined with temozolomide (TMZ). This demonstrates the significant clinical advantage of multimodal therapy, particularly TMZ's role in enhancing outcomes for GBM patients. Such findings validate the continued reliance on TMZ as the backbone of GBM therapy and reinforce the demand for chemotherapy drugs in combination protocols. The evidence also supports healthcare providers' preference for integrated treatment approaches, strengthening the adoption of combination therapies in clinical practice.

From a market perspective, this survival benefit will continue to drive investment in combination regimens and fuel demand for supportive therapeutics like TMZ. Pharmaceutical companies are expected to leverage these outcomes by developing next-generation therapies that complement or enhance TMZ's effects, including immunotherapies and targeted agents. The higher survival outcomes with RT+TMZ will influence treatment guidelines, leading to broader reimbursement coverage and increased uptake across hospitals and cancer centers. This shift will not only sustain the dominance of TMZ in the GBM treatment market but also create opportunities for novel adjunctive therapies positioned alongside it.

Global Glioblastoma Multiforme Treatment Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global glioblastoma multiforme treatment market report based on treatment, end use, and region:

  • Treatment Outlook (Revenue, USD Million, 2021 - 2033)
  • Surgery
  • Radiation Therapy
  • Chemotherapy
    • Temozolomide
    • Lomustine
    • Carmustine Wafers
    • Other
  • Targeted Therapy (Bevacizumab)
  • Tumor Treating Field (TTF) Therapy
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals
  • Clinics / Outpatient Centers
  • Ambulatory Surgical Centers
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment
    • 1.2.2. End Use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Glioblastoma Multiforme Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Glioblastoma Multiforme Treatment Market: Treatment Business Analysis

  • 4.1. Treatment Market Share, 2025 & 2033
  • 4.2. Treatment Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2021 to 2033 (USD Million)
  • 4.4. Surgery
    • 4.4.1. Surgery Market, 2021 - 2033 (USD Million)
  • 4.5. Radiation Therapy
    • 4.5.1. Radiation Therapy Market, 2021 - 2033 (USD Million)
  • 4.6. Chemotherapy
    • 4.6.1. Chemotherapy Market, 2021 - 2033 (USD Million)
    • 4.6.2. Temozolomide
      • 4.6.2.1. Temozolomide Market, 2021 - 2033 (USD Million)
    • 4.6.3. Lomustine
      • 4.6.3.1. Lomustine Market, 2021 - 2033 (USD Million)
    • 4.6.4. Carmustine Wafers
      • 4.6.4.1. Carmustine Wafers Market, 2021 - 2033 (USD Million)
    • 4.6.5. Other
      • 4.6.5.1. Other Market, 2021 - 2033 (USD Million)
  • 4.7. Targeted Therapy (Bevacizumab)
    • 4.7.1. Targeted Therapy (Bevacizumab) Market, 2021 - 2033 (USD Million)
  • 4.8. Tumor Treating Field (TTF) Therapy
    • 4.8.1. Tumor Treating Field (TTF) Therapy Market, 2021 - 2033 (USD Million)

Chapter 5. Glioblastoma Multiforme Treatment Market: End Use Business Analysis

  • 5.1. End Use Market Share, 2025 & 2033
  • 5.2. End Use Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 5.4. Hospitals
    • 5.4.1. Hospitals Market, 2021 - 2033 (USD Million)
  • 5.5. Clinics / Outpatient Centers
    • 5.5.1. Clinics / Outpatient Centers Market, 2021 - 2033 (USD Million)
  • 5.6. Ambulatory Surgical Centers
    • 5.6.1. Ambulatory Surgical Centers Market, 2021 - 2033 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Glioblastoma Multiforme Treatment Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2025 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 6.4. North America
    • 6.4.1. North America Glioblastoma Multiforme Treatment Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. U.S. Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. Uk Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Target Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Target Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Target Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Japan Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. China Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Target Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Target Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Target Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Target Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Merck & Co., Inc.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Treatment Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Amgen, Inc.
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Treatment Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. F. Hoffmann-La Roche Ltd.
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Treatment Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Pfizer Inc.
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Treatment Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Teva Pharmaceutical Industries Ltd.
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Treatment Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Sun Pharmaceutical Industries Ltd.
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Treatment Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Arbor Pharmaceuticals, LLC
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Treatment Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Amneal Pharmaceuticals
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Treatment Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Karyopharm Therapeutics, Inc.
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Treatment Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.)
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Treatment Benchmarking
      • 7.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global glioblastoma multiforme treatment market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 5 Global glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 6 North America glioblastoma multiforme treatment market, by country, 2021 - 2033 (USD Million)
  • Table 7 North America glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 8 North America glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 9 U.S. glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 10 U.S. glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 11 Canada glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 12 Canada glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 13 Mexico glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 14 Mexico glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 15 Europe glioblastoma multiforme treatment market, by country, 2021 - 2033 (USD Million)
  • Table 16 Europe glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 17 Europe glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 18 UK glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 19 UK glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 20 Germany glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 21 Germany glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 22 France glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 23 France glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 24 Italy glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 25 Italy glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 26 Spain glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 27 Spain glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 28 Norway glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 29 Norway glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 30 Denmark glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 31 Denmark glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 32 Sweden glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 33 Sweden glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 34 Asia Pacific glioblastoma multiforme treatment market, by country, 2021 - 2033 (USD Million)
  • Table 35 Asia Pacific glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 36 Asia Pacific glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 37 Japan glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 38 Japan glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 39 China glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 40 China glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 41 India glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 42 India glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 43 Australia glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 44 Australia glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 45 South Korea glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 46 South Korea glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 47 Thailand glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 48 Thailand glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 49 Latin America glioblastoma multiforme treatment market, by country, 2021 - 2033 (USD Million)
  • Table 50 Latin America glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 51 Latin America glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 52 Brazil glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 53 Brazil glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 54 Argentina glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 55 Argentina glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 56 Middle East & Africa Glioblastoma multiforme treatment market, by country, 2021 - 2033 (USD Million)
  • Table 57 Middle East & Africa glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 58 Middle East & Africa glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 59 South Africa glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 60 South Africa glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 61 Saudi Arabia glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 62 Saudi Arabia glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 63 UAE glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 64 UAE glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 65 Kuwait glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 66 Kuwait glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Glioblastoma multiforme treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape
  • Fig. 10 Glioblastoma multiforme treatment market dynamics
  • Fig. 11 Glioblastoma multiforme treatment market: Porter's five forces analysis
  • Fig. 12 Glioblastoma multiforme treatment market: PESTLE analysis
  • Fig. 13 Treatment market, 2021 - 2033 (USD Million)
  • Fig. 14 Surgery market, 2021 - 2033 (USD Million)
  • Fig. 15 Radiation therapy market, 2021 - 2033 (USD Million)
  • Fig. 16 Chemotherapy market, 2021 - 2033 (USD Million)
  • Fig. 17 Temozolomide market, 2021 - 2033 (USD Million)
  • Fig. 18 Lomustine market, 2021 - 2033 (USD Million)
  • Fig. 19 Carmustine Wafers market, 2021 - 2033 (USD Million)
  • Fig. 20 Other market, 2021 - 2033 (USD Million)
  • Fig. 21 Targeted therapy (Bevacizumab) market, 2021 - 2033 (USD Million)
  • Fig. 22 Tumor treating field (TTF) Therapy market, 2021 - 2033 (USD Million)
  • Fig. 23 End use market, 2021 - 2033 (USD Million)
  • Fig. 24 Hospitals market, 2021 - 2033 (USD Million)
  • Fig. 25 Clinics / outpatient centers market, 2021 - 2033 (USD Million)
  • Fig. 26 Ambulatory surgical centers market, 2021 - 2033 (USD Million)
  • Fig. 27 Others market, 2021 - 2033 (USD Million)
  • Fig. 28 Glioblastoma multiforme treatment market revenue, by region
  • Fig. 29 Regional marketplace: Key takeaways
  • Fig. 30 North America glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 31 U.S. country dynamics
  • Fig. 32 U.S. glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 33 Canada country dynamics
  • Fig. 34 Canada glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 35 Mexico country dynamics
  • Fig. 36 Mexico glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 37 Europe glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 38 UK country dynamics
  • Fig. 39 UK glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 40 Germany country dynamics
  • Fig. 41 Germany glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 42 France country dynamics
  • Fig. 43 France glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 44 Italy country dynamics
  • Fig. 45 Italy glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 46 Spain country dynamics
  • Fig. 47 Spain glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 48 Norway country dynamics
  • Fig. 49 Norway glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 50 Sweden country dynamics
  • Fig. 51 Sweden glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 52 Denmark country dynamics
  • Fig. 53 Denmark glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 54 Asia Pacific glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 55 Japan country dynamics
  • Fig. 56 Japan glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 57 China country dynamics
  • Fig. 58 China glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 59 India country dynamics
  • Fig. 60 India glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 61 Australia country dynamics
  • Fig. 62 Australia glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 63 South Korea country dynamics
  • Fig. 64 South Korea glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 65 Thailand country dynamics
  • Fig. 66 Thailand glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 67 Latin America glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 68 Brazil country dynamics
  • Fig. 69 Brazil glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 70 Argentina country dynamics
  • Fig. 71 Argentina glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 72 MEA glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 73 South Africa country dynamics
  • Fig. 74 South Africa glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 75 Saudi Arabia country dynamics
  • Fig. 76 Saudi Arabia glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 77 UAE country dynamics
  • Fig. 78 UAE glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 79 Kuwait country dynamics
  • Fig. 80 Kuwait glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 81 Company categorization
  • Fig. 82 Company market position analysis
  • Fig. 83 Strategic framework